HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER

Clinical trials for HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER trials appear

Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Terminated 1

Could a leukemia drug help fight breast cancer? new trial investigates

Disease control Terminated

This study tested whether adding a drug called ATRA (all-trans retinoic acid) to the standard hormone therapy anastrozole could shrink tumors more effectively in postmenopausal women with a common type of early breast cancer (HR-positive/HER2-negative). The trial was planned for …

Matched conditions: HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER

Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC

HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER

Get alerted when new HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER trials appear

Could a leukemia drug help fight breast cancer? new trial investigates